NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
SHC
Sotera Health Company
SHC has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Weak |
SHC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over SHC in the historical PE scenario, which offers more potential upside but is not a forecast.
SHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $16.30 | — |
| Current | 27x | $16.30 | — |
| Cheap | 38x | $23.00 | +41% |
| Fair | 61x | $36.40 | +123% |
| Expensive | 173x | $104 | +538% |
Historical ranges are pointers, not guarantees.
SHC's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
SHC has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
SHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.04 | +73% |
| Q3 2026 | $0.60 | +200% |
| Q2 2026 | $0.57 | +533% |
| Q1 2026 | $0.41 | +356% |
| Q4 2025 | $0.27 | +69% |
| Q3 2025 | $0.20 | -20% |
| Q2 2025 | $0.09 | -36% |
| Q1 2025 | $0.09 | -53% |
| Q4 2024 | $0.16 | -11% |
SHC earned $0.60 per share over the past year, about three times what it earned the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SHC on profitability, with a higher operating margin.
SHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $324.9M | +4.4% |
| Q2 2026 | $321.4M | +9.2% |
| Q1 2026 | $280M | +10% |
| Q4 2025 | $303.4M | +4.6% |
| Q3 2025 | $311.3M | +9.1% |
| Q2 2025 | $294.3M | +6.4% |
| Q1 2025 | $254.5M | +2.6% |
| Q4 2024 | $290.2M | -6.5% |
SHC's revenue has grown year over year for seven quarters in a row: $325M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | +2.3 points |
| Q2 2026 | 24% | +18 points |
| Q1 2026 | 15% | +21 points |
| Q4 2025 | 23% | -6.8 points |
| Q3 2025 | 23% | -4.8 points |
| Q2 2025 | 6.4% | -21 points |
| Q1 2025 | -5.8% | -27 points |
| Q4 2024 | 30% | -3.5 points |
SHC's operating margin was 26% last quarter, up 2.3 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
SHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57.7M | +65% |
| Q2 2026 | $42M | +61% |
| Q1 2026 | -$16.7M | -147% |
| Q4 2025 | $52.4M | +$62.6M |
| Q3 2025 | $35M | -43% |
| Q2 2025 | $26.2M | +35% |
| Q1 2025 | $35.6M | +$60.8M |
| Q4 2024 | -$10.2M | -121% |
SHC generated $135M in free cash flow over the past year, up 56% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +2.9% | +8.1M shares |
| 5 years | +3.5% | +9.7M shares |
| Available history | +3.7% | +10.4M shares |
SHC has 289M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over SHC on leverage, with a lower net debt burden relative to earnings.
SHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 4.6x | High |
| Q1 2026 | 5.5x | High |
| Q4 2025 | 6.3x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 5.7x | High |
| Q1 2025 | 4.9x | High |
| Q4 2024 | 4.2x | High |
SHC's net debt is about 4.3 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 20.9 | Neutral |
SHC's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over SHC on valuation relative to its sector.
SHC PE vs Healthcare Sector
| Metric | SHC | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 5.1% above |
| PE % | 8 | 34 | 26 pts below |
SHC is trading at 27x earnings, in line with the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.6 | 7.5% below |
| 20 week MA | $18.2 | 10% below |
| 50 week MA | $17.1 | 4.4% below |
| 100 week MA | $15.3 | 6.7% above |
| 200 week MA | $15.1 | 7.9% above |
SHC has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.1 | $26.9 | +7.3% |
| 2021 | $26.9 | $23.6 | -13% |
| 2022 | $23.6 | $7.93 | -66% |
| 2023 | $7.93 | $16.9 | +112% |
| 2024 | $16.9 | $13.5 | -20% |
| 2025 | $13.5 | $17.7 | +31% |
| 2026 YTD | $17.7 | $16.3 | -7.9% |
SHC has the edge over NVO on returns for 2026, with the stronger performance.